KO 947

Drug Profile

KO 947

Alternative Names: KO-947

Latest Information Update: 22 May 2017

Price : $50

At a glance

  • Originator Araxes Pharma
  • Developer Araxes Pharma; Kura Oncology
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Mitogen activated protein kinase 3 inhibitors; Mitogen-activated protein kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 19 Apr 2017 Kura Oncology has patent protection for KO 947 and structurally-related compounds in USA
  • 06 Apr 2017 Phase-I clinical trials in Solid tumours (Late-stage disease, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT03051035)
  • 04 Apr 2017 US FDA approves IND application for KO 947 in Solid tumours
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top